Anti-VEGF Agent Use in Diabetic Macular Oedema

Anti-VEGF Agent Use in Diabetic Macular Oedema

Diabetic macular oedema (DMO) is the most common cause of vision loss in patients with diabetic retinopathy, with an increasing prevalence tied to the global epidemic of type 2 diabetes mellitus. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of DMO and anti-vascular endothelial growth factor therapy (anti-VEGF) has emerged as first-line therapy.

Modern Medicine – Issue 3 2020